The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer. READ MORE
Women with HER2-positive breast cancer who received sequential trastuzumab did not experience a significant difference in overall survival or relapse-free survival when compared with women who received concurrent therapy.
Re-excision rates following breast-conserving surgery have significantly declined in the wake of professional society guideline implementation.
Women with HER2-positive and triple-negative breast cancer have an elevated risk of developing brain metastasis regardless of active systemic treatment receipt.
The average cost during the initial phase of breast cancer care for Medicare fee-for-service beneficiaries was $28,075 – $13,344 of which went toward physician services and $7456 for outpatient services.